Cogent Biosciences, Inc. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Cogent Biosciences filed an 8-K on 2026-09-01 disclosing entry into a material definitive agreement under Item 1.01. The filing provides no substantive details: no counterparty name, dollar amounts, terms, conditions, or business rationale are stated in the available text. The actual agreement terms are withheld.
Why this rating
Undisclosed material agreement creates uncertainty but without specifics—counterparty, value, or impact—cannot assess materiality. Relative to $773M market cap, unknown exposure prevents meaningful scoring.
Extracted items
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.